Chimerix, Inc. (CMRX)
Market Cap | 90.10M |
Revenue (ttm) | 324,000 |
Net Income (ttm) | -82.10M |
Shares Out | 89.21M |
EPS (ttm) | -0.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 366,664 |
Open | 1.030 |
Previous Close | 1.010 |
Day's Range | 1.005 - 1.090 |
52-Week Range | 0.880 - 1.570 |
Beta | 1.16 |
Analysts | Strong Buy |
Price Target | 8.00 (+654.72%) |
Earnings Date | May 2, 2024 |
About CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CMRX stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 654.72% from the latest price.
News
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Appoints Lisa Decker to Board of Directors
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Exp...
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix's Board of Directors granted an inducement awa...
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry...
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a ...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients faci...
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients faci...
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 –
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –
Chimerix Responds to Rubric Capital Management
Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans
Rubric Capital Management Sends Letter to Chimerix Board of Directors
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“C...
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November –
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing ...
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -